Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Investigating the data from the Phase 3 ZENITH clinical trial of Winrevair (Sotatercept-csrk) in patients with PAH.

Ticker(s): MRK

Who's the expert?

Institution: Trinity Health

Board certified in Pulmonology, Critical Care, and Internal medicine,
treats 153 patients with IPF
familiar with the data and outcomes for trials on PLN-74809

Interview Goal

to discuss the current treatment landscape and the potential of Winrevair (Sotatercept-csrk), an activin signaling inhibitor being developed by Merck for the treatment of PAH.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.